Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03322748
Other study ID # OVERACT V1
Secondary ID
Status Not yet recruiting
Phase N/A
First received October 13, 2017
Last updated January 9, 2018
Start date February 2018
Est. completion date February 2020

Study information

Verified date January 2018
Source IRCCS San Raffaele
Contact Giancarlo Comi, MD
Phone 0226432990
Email giancarlo.comi@hsr.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study (OVERACT_V1) is to verify if the isometric contraction of ankle plantarflexor and Hamstring muscles, induces a significant reduction of overactive bladder symptoms in patients with Multiple sclerosis.


Description:

The aim of the study (OVERACT_V1) is to verify if the isometric contraction of ankle plantarflexor and Hamstring muscles, induces a significant reduction of overactive bladder symptoms in patients with Multiple sclerosis. It's known that the electric stimulation of the Posterior Tibial nerve induces an improvement of overactive bladder symptoms through a modulation of spinal circuitry, which occurs with unknown mechanisms. The investigators' hypothesis is that the voluntary muscular activation may induce a modulation of the sacral root as long as the electric stimulation. 30 patients will be recruited within 2 years, since October 2017 through October 2019. This is a monocentric, randomized controlled , in single blind, not pharmacological study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date February 2020
Est. primary completion date February 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Multiple Sclerosis Patients

- Urge score >=2

- urinary daytime frequency >=8

- stable overactive bladder symptoms for 6 months

- MRC ( Medical Research Council) scale of ankle plantarflexors and hamstrings >=2

- signed informed consensus

Exclusion Criteria:

- FIM ( Functional Independence Measure) memory items <=4

- impairment in registering bladder diary

- inclusion in other experimental study

- specific straightening during the suty period

- PVR >= 200 ml ina single evaluation or PVR (post void residual) >=150 in 4 evaluation (twice a day for 2 consecutive days)

- Urinary infections

- concomitant urological disease

- intrathecal baclofen pump

- SANS (Stoller Afferent Nerve Stimulation)

- modification of therapy for overactive bladder symptoms within three months before entering the study

Study Design


Intervention

Other:
Usual physical therapy+ strengthening of lower limbs muscles
Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
Usual physical therapy
Usual physical therapy

Locations

Country Name City State
Italy Prof. Giancarlo Comi Milan MI

Sponsors (1)

Lead Sponsor Collaborator
IRCCS San Raffaele

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Urinary frequency mean of voluntary urination episodes daytime during 4 days of bladder diary at 6th and 22nd day
Primary Change of Urge score mean of score evaluating the perception of urge that patient experiences every urination. The subscale scores are:
0, if patient doesn't need to urinate, but urinates before going out from home or concerned about the unavailability of toilet;
1, if patient doesn't experience urgent urination;
2, presence of urgency but disappeared before getting to the toilet;
3, presence of urgency and reached the toilet without leakage of urine
4, presence of urgency and did not reach the toilet with leakage of urine
at 6th and 22nd day
Primary Change of total score of OAB-q ( Overact Bladder questionnaire) long form questionnaire evaluates the impact of overactive bladder symptoms on activities of daily living 8 ITEMS SYMPTOM BOTHER (each item has a subscale score from 1 to 6) + 25 ITEMS HEALTH-RELATED QUALITY OF LIFE (each item has a subscale score from 1 to 6) at 3rd and 18th day
Secondary Change of Urine volume Minimum , maximum and mean of urine volume voiding during 4 days of bladder diary at 6th and 22nd day
Secondary Change of episodes of urinary incontinence Mean of involuntary leakage of urine during 4 days of bladder diary at 6th and 22nd day
Secondary Change of episodes of nocturia Mean of voluntary urination episodes nightime during 4 days of bladder diary at 6th and 22nd day
Secondary Change of Postvoid Residual Volume Mean of 3 measurement of Urine residual after voluntary voiding at 3rd and 18th day
Secondary Change of Pad-test 24 Hours Mean of numbers and weight of pads at 6th and 22nd day
Secondary PGI (Patient global impression of improvement) Questionnaire on subjective impression of improvement of overactive bladder symptoms at 18th day
Secondary Change of value at Uroflussimetry Mean of maximum urinary flow rate (Qmax) value at uroflussimetry at 3rd and 18th day
Secondary Change of value at "H REFLEX" test Evaluation of H wave mean amplitude and of Ratio of maximum H reflex to maximum M response after a train of stimuli given at 1 and 0.1 Hz at 6th and 22nd day
Secondary Change of EDSS (Expanded Disability Status Scale) Mean of value at EDSS that quantifying disability in multiple sclerosis at 2nd and 22nd day
Secondary Change of Barthel Index Score Mean of total score measuring performance in activities of daily living at 2nd and 22nd day
Secondary Change of MAS (Modified Ashworth Scale ) Mean of score (0-4) measuring spasticity of plantarflexors and Hamstring muscles at 2nd and 22nd day
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4